Robert Reiter, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Lantheus
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Point biopharma
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Specialty Not Specified)
    Ineligible company: 
    Genomic Health
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Investment Interest (Specialty Not Specified)
    Ineligible company: 
    ImaginAb Corporation
    Mitigation strategy: 
    Attest
    Date reviewed: 
    06/13/2022
Return to Curso en vivo de avances globales en cáncer de próstata: mejores prácticas en terapia hormonal (2022) - Espanol